Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report

IF 16.4 1区化学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Accounts of Chemical Research Pub Date : 2024-08-01 DOI:10.1016/j.anorl.2024.02.003

{"title":"Nivolumab immunotherapy rechallenge for progressive laryngeal squamous cell carcinoma after failure of conventional treatment: A CARE case report","authors":"","doi":"10.1016/j.anorl.2024.02.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>Analysis of rechallenge with nivolumab<span> as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma<span> following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.</span></span></p></div><div><h3>Observation</h3><p><span><span>A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with </span>chemoradiotherapy<span> and surgery, was initially treated for recurrence with carboplatin<span>, 5-fluorouracile (FU) and cetuximab<span><span>, followed by second-line nivolumab<span>, and then two lines of conventional chemotherapy with paclitaxel and </span></span>cetuximab<span> followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12</span></span></span></span></span>  <!-->months’ survival since initiation of exclusive systemic management after failure of conventional treatment.</p></div><div><h3>Conclusion</h3><p>This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.</p></div>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1879729624000206","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective

Analysis of rechallenge with nivolumab as 5th-line therapy for locally and nodally failed laryngeal squamous cell carcinoma following conventional therapeutic modalities: radiotherapy, surgery and chemotherapy.

Observation

A 70-year-old male, with local and nodal progression of laryngeal squamous cell carcinoma after treatment with chemoradiotherapy and surgery, was initially treated for recurrence with carboplatin, 5-fluorouracile (FU) and cetuximab, followed by second-line nivolumab, and then two lines of conventional chemotherapy with paclitaxel and cetuximab followed by carboplatin and cetuximab. He underwent rechallenge with nivolumab in 5th line, achieving 12 months’ response, ongoing at the time of writing, and 42.5 months’ survival since initiation of exclusive systemic management after failure of conventional treatment.

Conclusion

This case report highlights the benefit of nivolumab rechallenge in 5th line following previous failure as stand-alone therapy in 2nd line for a patient with laryngeal squamous cell carcinoma locally and nodally uncontrolled after conventional treatment. Clinical trials evaluating the efficacy of this approach are necessary to assess its contribution, as it is currently not a standard therapeutic option.

查看原文本刊更多论文

常规治疗失败后，Nivolumab 免疫疗法再挑战治疗进展期喉鳞癌：CARE病例报告

在采用放疗、手术和化疗等常规治疗方法后，对局部和结节治疗失败的喉鳞癌进行再挑战nivolumab作为五线疗法的分析。一位70岁的男性患者在接受化放疗和手术治疗后，喉鳞状细胞癌出现局部和结节进展，他最初接受了卡铂、5-氟尿嘧啶（FU）和西妥昔单抗的复发治疗，随后接受了二线尼伐单抗治疗，之后又接受了紫杉醇和西妥昔单抗的两线常规化疗，之后又接受了卡铂和西妥昔单抗治疗。他在第五线接受了 nivolumab 的再挑战，获得了 12 个月的应答，在撰写本报告时仍在进行中，并且自常规治疗失败后开始接受独家系统治疗以来获得了 42.5 个月的生存期。本病例报告强调了在常规治疗后局部和结节未受控制的喉鳞癌患者，在二线独立治疗失败后，在五线接受尼妥珠单抗再挑战治疗的益处。有必要进行临床试验，评估这种方法的疗效，因为它目前还不是标准治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Accounts of Chemical Research 化学-化学综合

CiteScore

31.40

自引率

1.10%

发文量

312

审稿时长

2 months

期刊介绍： Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.